Journal Guide

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.

Expert Opinion on Therapeutic Patents ranks #3 of 13 in the Medicine, Legal category and #118 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. * Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area * Patent Evaluations examining the aims and chemical and biological claims of individual patents * Perspectives on issues relating to intellectual propertyThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D.

Expert Opinion on Therapeutic Targets ranks #53 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on recently identified novel molecular drug targets, providing expert opinion on the scope for future development and impact on drug discovery.The Editors welcome: * Reviews covering novel disease targets at the molecular level and their implications on future drug development * Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugsThe audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D.Read More: http://informahealthcare.com/page/Description?journalCode=ett.

Expert Review of Precision Medicine and Drug Development publishes original research and review articles covering the development and clinical application of medicine to be used in a personalized therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include:

• Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. 
• Clinical trials and case studies within personalized therapy and drug development. 
• Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment.
• Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. 
• Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.

Expert Review of Vaccines (ISSN 1476-0584) provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism. All articles are subject to rigorous peer-review.

Fitoterapia is a Journal dedicated to medicinal plants and to bioactive natural products of plant origin. It publishes original contributions in seven major areas:1. Characterization of active ingredients of medicinal plants2. Development of standardization method for bioactive plant extracts and natural products3. Identification of bioactivity in plant extracts4. Identification of targets and mechanism of activity of plant extracts5. Production and genomic characterization of medicinal plants biomass6. Chemistry and biochemistry of bioactive natural products of plant origin7. Critical reviews of the historical, clinical and legal status of medicinal plants, and accounts on topical issues.Contributions reporting the following are not normally considered for publication:1. Activity data on crude extracts that have not been characterized by analysis of their major constituents (HPLC, NMR);2. Unexceptional and predictable bioactivity (e.g. antioxidant properties of phenolics or antibacterial activity of essential oils);3. Uncritical ethnopharmacological investigations, where a list of plants and their use are simply recorded.The following immediate rejection criteria apply:RULE 1: The manuscript does not fall into any of the areas of interest of the Journal;RULE 2: The manuscript is too preliminary, reporting e.g. activity data without comparison to a reference, or without a positive control;RULE 3: The botanical source is not clearly identified, authenticated, and documented (voucher);RULE 4: Bioactivity is not relevant to in vivo situations.The journal encourages Authors to enhance the description of their methodological procedures by submitting accompanying multimedia files (video or animation sequences). These files are to be submitted as supplementary material, see below.The journal publishes supplements, podcasts and webinars. For sponsorship opportunities please contact a.pordon@elsevier.com.

Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including:

Medicinal chemistry has evolved rapidly into a highly interdisciplinary field, enriched by the collaborative efforts of experts from a wide spectrum of specialist areas, from chemoinformaticians and physical chemists to molecular biologists and pharmacologists. Future Medicinal Chemistry provides a monthly point of access to commentary and debate for this ever-expanding and diversifying community. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research, from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.

C. elegans RDE-4 is a double-stranded RNA binding protein that has been shown to play a key role in response to foreign double-stranded RNA (dsRNA). We have used diverse tools for analysis of gene function to characterize the domain and organismal foci of RDE-4 action in C. elegans. First, we examined the focus of activity within the RDE-4 protein, by testing a series of RDE-4 deletion constructs for their ability to support dsRNA-triggered gene silencing. These assays indicated a molecular requirement for a linker region and the second dsRNA-binding domain of RDE-4, with ancillary contributions to function from the C and N terminal domains. Second, we used mosaic... continue reading.

he journal Immunopharmacology and Immunotoxicology is devoted to preclinical and clinical studies about the regulatory effects of various agents on immunocompetent cells as well as the immunotoxicity exerted by xenobiotics and drugs. On these bases, the journal encompasses a broad range of pathologies (e.g., acute and chronic infections, allergy, autoimmunity, cancer, degenerative disorders, inflammation and primary and secondary immunodeficiencies).In this framework, the journal will cover new emerging areas of science of broad interest, such as agricultural biotechnology; atherosclerosis; cytokine and growth factor regulation; dendritic cell therapy; food immunology and safety; forensic immunopathology; innate immunity regulation; microbial immunomodulators; mucosal immunity; drug development; psychoneuroimmunology; stem cell therapy; veterinary immunopathology; and vaccines. While articles related to purified extracts may be considered, research on crude botanical extracts are discouraged.Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, invited reviews, and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).Read More: http://informahealthcare.com/page/ipi/Description.

The aim of the International Institute of Anticancer Research (IIAR) is to provide an independent platform for international cooperation in the fight against cancer. The IIAR will advance, protect and support throughout the world the ideals of freedom, peace, health, scientific knowledge, equality, welfare and mutual respect among communities in science and life.This site provides information on the aims and activities of the IIAR, including current cancer research projects and invitations for cooperation.The IIAR is supported by the three international peer-reviewed journals ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS which are also available online through the Stanford University HighWire Press.

The Indian Journal of Pharmacology (ISSN 0253-7613) is an official organ of the Indian Pharmacological Society. The first issue of the journal came out in 1969 and it was published Bimonthly. In 1997 it became a bimonthly publication. IJP publishes original research articles, reviews, research letters and correspondences.